MK-4700 / Merck (MSD) - LARVOL DELTA

A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001) (clinicaltrials.gov) - P1 | N=5 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed | N=82 ➔ 5

Enrollment change • Monotherapy • Trial completion • Oncology • Solid Tumor

A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001) (clinicaltrials.gov) - P1 | N=82 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting | Trial completion date: Oct 2029 ➔ Nov 2025 | Trial primary completion date: Oct 2029 ➔ Nov 2025

Enrollment closed • Monotherapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001) (clinicaltrials.gov) - P1 | N=82 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor